Research Article
The Efficacy of Pegylated Liposomal Doxorubicin-Based Neoadjuvant Chemotherapy in Breast Cancer: A Retrospective Case-Control Study in Taiwan
Table 3
Cox proportional hazard regression model of overall survival.
| Characteristics | Univariate analysis | Multivariate analysis | HR (95% CI) | | HR (95% CI) | |
| PLD group vs. epirubicin group | 1.62 (0.84–3.11) | 0.152 | 1.36 (0.69–2.68) | 0.373 | Pathologic complete response (pCR) vs. non-pCR | 0.14 (0.02–1.04) | 0.055 | 0.12 (0.02–0.88) | 0.037 | Matching criteria | | | | | Preoperative clinical stage (III vs. I-II) | 1.75 (0.86–3.54) | 0.121 | 0.78 (0.32–1.93) | 0.596 | Molecular subtype | | | | | Luminal type (Her2 negative) | 1.00 | | 1.00 | | Her2 positive | 1.96 (0.91–4.23) | 0.087 | 1.81 (0.8–4.13) | 0.157 | TNBC | 3.14 (1.38–7.13) | 0.006 | 2.25 (0.87–5.82) | 0.096 | Chemoregimen before surgery with taxane vs. without taxane | 1.96 (0.91–4.23) | 0.086 | 2.40 (1.09–5.25) | 0.029 | Histological grade (III vs. I-II) | 3.95 (1.99–7.83) | <0.001 | 2.71 (1.28–5.76) | 0.009 | Age | 1.04 (1.00–1.07) | 0.063 | 1.01 (0.98–1.05) | 0.532 | Tumor size (mm) | 1.02 (1.01–1.03) | <0.001 | 1.02 (1.01–1.03) | <0.001 |
|
|